Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross-Trial Synthesis of Benefit Probabilities and Decision Thresholds.
OBJECTIVES: To synthesize published placebo-controlled trials of vibegron monotherapy for overactive bladder (OAB) and quantify posterior probabilities of benefit and decision-threshold exceedance. CONCLUSIONS: Bayesian cross-trial synthesis demonstrates a high probability that vibegron improves key OAB voiding-diary outcomes at Week 12.
OBJECTIVES: To synthesize published placebo-controlled trials of vibegron monotherapy for overactive bladder (OAB) and quantify posterior probabilities of benefit and decision-threshold exceedance. CONCLUSIONS: Bayesian cross-trial synthesis demonstrates a high probability that vibegron improves key OAB voiding-diary outcomes at Week 12.
What the study was
- Study design
- Randomized controlled trial
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- Lower urinary tract symptoms
Why it surfaced
High-priority Sentinel scan study: novel treatment potential warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.